A newborn at 2 hours of age has a blood glucose level of 35 mg/dL. The infant is jittery, has a weak cry, and shows poor feeding behavior. What is the most appropriate immediate nursing intervention?

Severe neonatal hypoglycemia with symptoms like jitteriness and poor feeding requires immediate IV glucose administration to prevent neurological damage. Other options are less urgent or inappropriate for symptomatic hypoglycemia.

Understanding the Clinical Presentation
A blood glucose level of 35 mg/dL in a 2-hour-old newborn is significantly below the commonly accepted operational threshold for intervention. The clinical signs described—jitteriness, a weak cry, and poor feeding—are classic manifestations of neuroglycopenia, where the brain is not receiving an adequate supply of glucose to meet its high metabolic demands. These symptoms indicate that the infant’s central nervous system is already being affected, moving this situation from a simple biochemical value to a symptomatic hypoglycemic event requiring urgent action ^[1].

Analyzing the Intervention Options
The priority is to rapidly restore brain fuel supply while identifying the safest, most effective route for this specific presentation.

- Option 1 (Administer oral glucose gel): While buccal dextrose gel is an effective first-line therapy for asymptomatic hypoglycemia in at-risk late preterm and term infants, its use is generally reserved for infants who are neurologistically intact and able to protect their airway and swallow safely. This infant’s poor feeding behavior and weak cry suggest a depressed level of consciousness, which increases the risk of aspiration. Administering an oral agent in this context is unsafe ^[1].
- Option 2 (Encourage frequent breastfeeding): Breastfeeding is the gold standard for prevention and management of asymptomatic transitional hypoglycemia. However, an infant exhibiting neuroglycopenic symptoms like jitteriness and a weak cry is neurologically compromised and unlikely to feed effectively. Relying on oral intake during a symptomatic episode delays the immediate correction of blood glucose and can lead to further clinical deterioration ^[1].
- Option 3 (Wrap warmly and recheck): Providing a neutral thermal environment is an essential supportive care measure, as hypothermia can increase metabolic rate and glucose consumption. However, in the presence of overt neurological symptoms, watchful waiting is contraindicated. Delaying definitive treatment to recheck glucose in an hour risks prolonged neuroglycopenia and potential neuronal injury ^[1].
- Option 4 (Notify provider for possible IV glucose): This is the correct escalation pathway. Symptomatic hypoglycemia constitutes a medical emergency. The most immediate nursing action is to notify the healthcare provider to obtain a stat order for an intravenous (IV) bolus of dextrose, typically 2 mL/kg of D10W. IV administration delivers glucose directly into the bloodstream, bypassing the gastrointestinal tract and providing the most rapid and reliable correction of severe, symptomatic hypoglycemia. This aligns with the escalation pathways recommended in major clinical guidelines when neurological signs are present ^[1].

Clinical Guideline Context and Safety
A systematic review of international guidelines highlights that while definitions and screening for neonatal hypoglycemia vary, the management of symptomatic hypoglycemia is consistently treated as an urgent scenario. The threshold for IV therapy is reached not only by a specific numerical value but by the presence of clinical signs. In a study from a Turkish tertiary care center, hypoglycemia was defined as a blood glucose level lower than 40 mg/dL, and the clinical context dictated the aggressiveness of the intervention ^[3]. A prospective cohort study from Tanzania further reinforces that neonatal hypoglycemia is a significant contributor to morbidity, and prompt, appropriate management of symptomatic cases is critical to improving early outcomes ^[2]. The nurse’s role is to recognize the decompensating physiology—where the infant’s symptoms indicate a failure of counter-regulatory mechanisms—and initiate the chain of command for definitive parenteral therapy without delay ^[1].